Connetics Corporation
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Connetics Corporation - overview
Established
1993
Location
Palo Alto, CA, US
Primary Industry
Pharmaceuticals
About
Connetics Corporation specializes in developing and manufacturing innovative therapies and products aimed at treating skin conditions, leveraging extensive research and clinical expertise to improve patient health outcomes. Founded in 1993 in Palo Alto, US, Connetics Corporation focuses on providing specialized treatments for dermatological conditions. The company was acquired by Stiefel Laboratories in December 2006, which further integrated its offerings into a broader portfolio. Connetics has participated in 2 investment deals, with its latest funding round being a PIPE investment of USD 12.
60 mn in December 2006, which also represents the total amount raised by the company. Connetics Corporation's product offerings are centered on dermatological therapies targeting various skin conditions. The company's research and development efforts prioritize innovative treatments designed to enhance patient care and manage skin health effectively. Their client base includes healthcare providers and institutions across North America, Europe, and Asia-Pacific, emphasizing their commitment to making healthcare accessible.
In the most recent reported year, Connetics Corporation generated revenue of USD 184. 26 mn, with an EBITDA of USD 40. 54 mn for the same year. Connetics Corporation is focused on launching new dermatological products and expanding into additional markets, specifically targeting regions in Europe and Asia by the end of 2024.
The funding from the recent PIPE in December 2006 is expected to support these initiatives, facilitating the development of innovative therapies and strengthening market presence following the company's acquisition.
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.connetics.com
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Connetics Corporation - financials
| Fiscal Year Ended | Dec 31, 2001 | Dec 31, 2002 | Dec 31, 2003 | Dec 31, 2004 | Dec 31, 2005 |
|---|---|---|---|---|---|
| Revenue (USD) | 34,064,000 | 52,763,000 | - | - | - |
| % Revenue Growth (YoY) | - | 54.9% | - | - | - |
| EBITDA (USD) | (24,489,000) | (17,439,000) | - | - | - |
| Operating Income (USD) | (26,499,000) | (19,534,000) | - | - | - |
| Operating Margin | (77.8%) | (37.0%) | - | - | - |
| % EBITDA Margin | (71.9%) | (33.1%) | - | - | - |
| NET Income (USD) | (16,742,000) | (16,590,000) | - | - | - |
| % Net Margin | (49.1%) | (31.4%) | - | - | - |
Connetics Corporation - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.